Business
Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting
Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting ...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nNotice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nNotice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting\nCanada NewsWire\nMISSISSAUGA, ON, April 22, 2016\n\n\n\nMISSISSAUGA, ON, April 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\" or \"the Company\") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 5, 2016. \n\nQ1 2016 CONFERENCE CALL\n\nWHEN: Thursday, May 5, 2016 at 8:30AM ET\n\nCONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.com or http://bit.ly/1SoKaaO.  An archived replay of the webcast will be available for 90 days.\n\nANNUAL AND SPECIAL MEETING\n\nWHEN: Thursday, May 5, 2016 at 11:00AM ET\n\nWHERE: Goodmans LLP, Bay Adelaide Centre, 333 Bay Street, Suite 3400, Toronto, Ontario, M5H 2S7\n\nAbout Cipher Pharmaceuticals Inc.\n\nCipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products with the goal of becoming the most customer-centric dermatology company in North America.\n\nCipher completed seven transactions in 2015, including the acquisition of Innocutis and its nine branded dermatology products, to build its U.S. commercial presence, expand its Canadian dermatology franchise and broaden its pipeline. Cipher is well-capitalized to drive long-term, sustained earnings growth by leveraging its proven clinical development capabilities and efficient commercial execution. For more information, visit www.cipherpharma.com.\nSOURCE Cipher Pharmaceuticals Inc.\n\n\n\n\n\n\nInvestors: In Canada: Craig Armitage, LodeRock Advisors, (416) 347-8954, [email protected]; In the United States: Thomas Hoffmann, The Trout Group LLC, (64...